-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Biopharmaceutical company Puma Biotechnology recently published the interim results of a queue of patients with metastasis non-small cell lung cancer (NSCLC) who had previously received EGFR-targeted tyrosine kinase inhibitors (TKI) in the treatment of 18 mutations in the exoskeleton exoskeleton (EGFR).
results were announced at the World Lung Cancer Conference (WCLC 2020) in Singapore.
SUMMIT Phase II clinical trial is an open, multi-center, multi-country study designed to assess the safety and ability of neratinib to treat metastasis non-small cell lung cancer patients with EGFR exon 18 mutations.
in the EGFR exon 18 mutation queue, the patient received prior treatment in the transfer environment prior to entering the trial (the medium previous treatment line was 2, ranging from 1-3).
results of the trial showed that 6 patients (60%) of the 10 patients who had previously received TKI treatment experienced partial remission and 8 patients (80%) experienced clinical benefits.
the medium mitigation time was 7.5 months and the medium non-progression lifetime was 9.1 months.
